issues

January 2013

Download PDF

COVER

PLATFORM TECHNOLOGY – Tumor-Targeting Platform Delivers the Next Generation of Pediatric Cancer Drugs

Contributor Cindy H. Dubin examines the desperate need for therapies that can address underserved populations, eradicate the cancer state without severe complications, and prolong the lifespan of the patient after diagnosis, and how NanoSmart Pharmaceuticals, with its unique tumor-targeting platform, has taken on that challenge.

FEATURES

DRUG DELIVERY – HEPtune: A Process of Conjugating a Naturally Occurring Sugar Molecule, Heparosan, to a Drug for Enhanced Drug Delivery

Paul L. DeAngelis, PhD, shows how heparosan is a stealthy molecule well suited for use as a drug delivery vehicle due to its natural origin and properties in the body. Therefore, heparosan-modified therapeutics may offer improved pharmacokinetics, drug performance properties, as well as new options for treatment and hope for patients.

DRUG DEVELOPMENT – Analysis & Materials Characterization – Surface Characterization of Pharmaceuticals by X-Ray Photoelectron Spectroscopy

Jeffrey Shallenberger, MS; and Robert W. Lee, PhD; use X-ray photoelectron spectroscopy (a quantitative, surface-sensitive spectroscopy capable of probing the local chemical bonding of inorganic and organic materials) to quantify the amount of an API and two excipients.

EXECUTIVE INTERVIEW – Ariel Pharmaceuticals, Inc: Reducing Shareholder Risk Through Expedited Clinical Development

Executive Summary: Steve Orndorff, President and CEO of Ariel, discusses his company's drugs in development and plans for the future.

EXECUTIVE INTERVIEW – Aptalis Pharmaceutical Technologies: Patient Centric Drug Delivery

Robert Becker, PhD, Chief Research Officer at Aptalis Pharma, discusses Patient Centric Drug Delivery and the company's role in supporting patient compliance and driving commercial value through new drug formulations.

DRUG DELIVERY – EyeSol: a Novel Topical Ocular Drug Delivery System for Poorly Soluble Drugs

Dieter Scherer, PhD; Eva Alvarez-Gonzalez, PhD; and Anthony Pettigrew, MSc; examine a proprietary non-protic, aqueous-free ocular delivery system with the potential to provide an alternative approach in particular for poorly soluble drugs.

MARKET BRIEF – Healthcare Growth Opportunities: Is Brazil the Next Big Thing in Healthcare?

Frost & Sullivan Analysts Swathi Allada, MBA, and Willian Fujioka believe the Brazilian healthcare market is poised for rapid growth, and the major revenue will come from the pharmaceutical/biotech sector, followed by medical devices, medical imaging, clinical diagnostics, and healthcare IT.

DRUG DEVICES – Inhalers: Can’t Use, Won’t Use

Kate Farmer, PhD, MBA; Kate Farrell, MEng; Andy Pidgeon; and Anna Rickard, PhD; provide some insight into the reasons behind the low levels of compliance and focus not only on the patient, but consider what the healthcare industry could be doing to tackle the problems.

EXECUTIVE INTERVIEW – Metrics Inc.: Poised for Growth in Contract, Proprietary & Generic Pharmaceuticals

Phil Hodges, who will continue to serve as President of Metrics, talks about how he will guide the company's future direction and growth, and what the recent transaction means for Metrics, Mayne, and their customers.

FORMULATION DEVELOPMENT – Peptide-Based Cancer Therapeutics

Jyothi Thundimadathil, PhD, indicates that even though shorter in vivo half-life of peptides is a concern, recent advances in drug delivery systems and peptide modification are expected to override those difficulties.

MANAGEMENT INSIGHT – Pharming Infertile Fields: Three Strategies for Growth in a Going-Nowhere Economy

In a healthy growing economy, you and I are both business oracles. We plow investments into fertile fields and they grow. Success is a ripe apple in arm's reach. It's..

PLATFORM TECHNOLOGY – Tumor-Targeting Platform Delivers the Next Generation of Pediatric Cancer Drugs

Contributor Cindy H. Dubin examines the desperate need for therapies that can address underserved populations, eradicate the cancer state without severe complications, and prolong the lifespan of the patient after diagnosis, and how NanoSmart Pharmaceuticals, with its unique tumor-targeting platform, has taken on that challenge.

Share This